Dacheng Wen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dacheng Wen has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Weidong Jiang
The Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Jilin University, Changchun, 130041, PR China
2 shared publications- Fangying Yin
Department of Pediatrics The China‐Japan Union Hospital of Jilin University Changchun China
1 shared publication Lili Zhong
Jilin Provincial Key Laboratory on Molecular and Chemical Genetic, The Second Hospital of Jilin University, Changchun, 130041, PR China
1 shared publicationXiumin Liu
Department of Clinical Laboratory, The Second Hospital of Jilin University, Changchun, 130041, PR China
1 shared publication- Yongsheng Yang
Department of Hepatobiliary and Pancreatic Surgery, Changchun, Jilin Province, China
1 shared publication Zhaohua Cheng
Department of Hepatobiliary Surgery The Second Hospital of Jilin University Changchun Jilin Province China
1 shared publication
Latest Publications
- 1 March 2021
- Published by Elsevier in Pancreatology
- Vol. 21 (2) , 406-417
Repression of circRNA_000684 inhibits malignant phenotypes of pancreatic ductal adenocarcinoma cells via miR-145-mediated KLF5
- 1 March 2021
- Published by Elsevier in Pancreatology
- Vol. 21 (2) , 406-417
Repression of circRNA_000684 inhibits malignant phenotypes of pancreatic ductal adenocarcinoma cells via miR-145-mediated KLF5
- 15 September 2018
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 32 (12) , e22220
Effect of sitagliptin, a DPP‐4 inhibitor, against DENA‐induced liver cancer in rats mediated via NF‐κB activation and inflammatory cytokines
The target of the current research was to investigate the anticancer activity of sitagliptin on diethylnitrosamine (DENA)‐induced cancer in the liver. Wistar rats were treated with or without sitagliptin before DENA treatment. We detected liver weight, blood glucose, and histopathology of the liver. Serum biochemical markers like serum glutamate pyruvate transaminase (SGPT), serum glutamate oxaloacetate transaminase (SGOT), serum alkaline phosphatase (SALP), gamma‐glutamyl transpeptidase (GGTP), total bilirubin (TBR), total protein (TPR), and albumin (ALB) were also evaluated. In addition, lipid profile parameters comprising total cholesterol (TC), triglycerides, and high‐density lipoprotein were also measured. Inflammatory mediators like interleukin‐6 (IL‐6), interleukin‐1beta (IL‐1β), and tumor necrosis factor‐alpha (TNF‐α) were determined in liver homogenate. Furthermore, the activity of nuclear factor (NF‐κB) was also measured. Our results showed that sitagliptin (10 and 20 mg/kg) in a dose‐dependent manner expressively decreased the DENA‐induced elevation of SGPT, SGOT, SALP, and GGTP. Whereas sitagliptin (10 and 20 mg/kg) in a dose‐dependent mode reduced the level of TBR and increased the TPR and ALB as well as improved the liver histopathology alterations in DENA‐exposed rats. Lipid profile was also restored by the sitagliptin (10 and 20 mg/kg) in a DENA‐treated rats. The level of IL‐1β, IL‐6, and TNF‐α were suggestively suppressed. Moreover, pretreatment with sitagliptin (10 and 20 mg/kg) prevented the activation of NF‐κB. In conclusion, sitagliptin (10 and 20 mg/kg) has a potential protective effect against DENA‐induced liver cancer by inhibition of inflammation and NF‐κB activation.
- 15 September 2018
- Published by Wiley in Journal of Biochemical and Molecular Toxicology
- Vol. 32 (12) , e22220
Effect of sitagliptin, a DPP‐4 inhibitor, against DENA‐induced liver cancer in rats mediated via NF‐κB activation and inflammatory cytokines
The target of the current research was to investigate the anticancer activity of sitagliptin on diethylnitrosamine (DENA)‐induced cancer in the liver. Wistar rats were treated with or without sitagliptin before DENA treatment. We detected liver weight, blood glucose, and histopathology of the liver. Serum biochemical markers like serum glutamate pyruvate transaminase (SGPT), serum glutamate oxaloacetate transaminase (SGOT), serum alkaline phosphatase (SALP), gamma‐glutamyl transpeptidase (GGTP), total bilirubin (TBR), total protein (TPR), and albumin (ALB) were also evaluated. In addition, lipid profile parameters comprising total cholesterol (TC), triglycerides, and high‐density lipoprotein were also measured. Inflammatory mediators like interleukin‐6 (IL‐6), interleukin‐1beta (IL‐1β), and tumor necrosis factor‐alpha (TNF‐α) were determined in liver homogenate. Furthermore, the activity of nuclear factor (NF‐κB) was also measured. Our results showed that sitagliptin (10 and 20 mg/kg) in a dose‐dependent manner expressively decreased the DENA‐induced elevation of SGPT, SGOT, SALP, and GGTP. Whereas sitagliptin (10 and 20 mg/kg) in a dose‐dependent mode reduced the level of TBR and increased the TPR and ALB as well as improved the liver histopathology alterations in DENA‐exposed rats. Lipid profile was also restored by the sitagliptin (10 and 20 mg/kg) in a DENA‐treated rats. The level of IL‐1β, IL‐6, and TNF‐α were suggestively suppressed. Moreover, pretreatment with sitagliptin (10 and 20 mg/kg) prevented the activation of NF‐κB. In conclusion, sitagliptin (10 and 20 mg/kg) has a potential protective effect against DENA‐induced liver cancer by inhibition of inflammation and NF‐κB activation.